PUBLISHER: The Business Research Company | PRODUCT CODE: 1939303
PUBLISHER: The Business Research Company | PRODUCT CODE: 1939303
Automated and closed cell therapy processing systems are integrated platforms designed to carry out multiple steps of cell therapy manufacturing within a sealed, controlled environment. These systems minimize manual handling, reducing contamination risks and ensuring the production of consistent, high-quality cell products. By automating processes such as cell isolation, expansion, and formulation, they enhance efficiency, reproducibility, and compliance with stringent regulatory standards.
The primary components of automated and closed cell therapy processing systems include software, hardware, and consumables. The software consists of specialized programs that control, monitor, and manage the sterile and precise manufacturing of cell-based therapies. These systems leverage technologies such as microfluidics, robotics, bioreactors, single-use technology, and three-dimensional (3D) cell culture. Key workflows include cryopreservation, separation, fill-finish, expansion, apheresis, and more. They are applied across fields such as oncology, regenerative medicine, autoimmune diseases, infectious diseases, and cardiovascular diseases, serving end users including pharmaceutical and biotechnology companies, research institutes, contract manufacturing organizations, and hospitals.
Tariffs are impacting the automated and closed cell therapy processing systems market by increasing the cost of imported hardware components, bioreactors, and single-use consumables. Segments such as robotics, microfluidics devices, and sterile consumables are most impacted, with regions like North America and Asia-Pacific experiencing higher import costs. This has led to elevated production and operational expenses. On the positive side, tariffs have encouraged local manufacturing investments, innovation in domestic solutions, and diversification of the global supply chain to reduce dependency on imports.
The automated and closed cell therapy processing systems market research report is one of a series of new reports from The Business Research Company that provides automated and closed cell therapy processing systems market statistics, including automated and closed cell therapy processing systems industry global market size, regional shares, competitors with a automated and closed cell therapy processing systems market share, detailed automated and closed cell therapy processing systems market segments, market trends and opportunities, and any further data you may need to thrive in the automated and closed cell therapy processing systems industry. This automated and closed cell therapy processing systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The automated and closed cell therapy processing systems market size has grown rapidly in recent years. It will grow from $1.53 billion in 2025 to $1.8 billion in 2026 at a compound annual growth rate (CAGR) of 17.6%. The growth in the historic period can be attributed to manual cell processing methods, high contamination risks, limited workflow automation, reliance on traditional bioreactors, slow adoption of regenerative therapies.
The automated and closed cell therapy processing systems market size is expected to see rapid growth in the next few years. It will grow to $3.34 billion in 2030 at a compound annual growth rate (CAGR) of 16.7%. The growth in the forecast period can be attributed to development of integrated closed-system platforms, advancements in robotics and microfluidics, growth of cell and gene therapy pipelines, rising regulatory compliance standards, increasing contract manufacturing organizations (cramos) for cell therapies. Major trends in the forecast period include increasing adoption of single-use and closed systems, rising demand for automated cell therapy workflows, focus on minimizing contamination and enhancing safety, integration of multi-step cell processing platforms, expansion of regenerative medicine and oncology applications.
The increasing demand for personalized medicine is anticipated to drive the growth of the automated and closed-cell therapy processing systems market in the coming years. Personalized medicine involves medical treatments customized to an individual's genetic, molecular, or cellular profile to enhance effectiveness and reduce adverse effects. This rising demand is fueled by stronger regulatory frameworks and incentives that favor the approval of targeted and curative therapies over broadly used drugs. Automated and closed-cell therapy processing systems facilitate personalized medicine by allowing manufacturers to produce consistent, high-quality, patient-specific cell therapies that comply with stringent regulatory requirements. For example, in May 2025, according to the Personalized Medicine Coalition (PMC), a US-based non-profit organization, the FDA approved 18 new personalized medicines in 2024, including six gene- or cell-based therapies, accounting for approximately 38 percent of all new molecular entities. As a result, the increasing demand for personalized medicine is propelling the growth of the automated and closed-cell therapy processing systems market.
Leading companies in this market are focusing on technological innovations, such as advanced cell preparation platforms, to enhance efficiency and maintain quality in cell therapy manufacturing. These platforms are automated systems designed to isolate, process, and prepare cells efficiently for clinical use or further analysis while reducing manual labor and contamination risks. In October 2024, Sino-Biocan Biotechnology Ltd., a China-based biotech company, launched the WUKONG Automated, Closed, Integrated Cell Processing System. This fully automated, closed platform streamlines the entire workflow from blood collection to cell culture and final filling. It is intended for hospitals, pharmaceutical R&D teams, and contract development and manufacturing organizations, offering improved efficiency, reduced contamination risks, and GMP-grade consistency through intelligent controls and real-time monitoring.
In March 2024, Donaldson Company Inc., a US-based filtration company, acquired Univercells Technologies for $157.28 million (€136 million). This acquisition strengthens Donaldson's capabilities in life sciences by integrating Univercells Technologies' automated and closed biomanufacturing platforms to provide end-to-end solutions for cell and gene therapy production. Univercells Technologies is a Belgium-based provider of automated and closed cell therapy processing systems.
Major companies operating in the automated and closed cell therapy processing systems market are Thermo Fisher Scientific Inc., Fresenius SE & Co. KGaA, Danaher Corporation, Merck KGaA, Parker Hannifin Corp., Corning Incorporated, Kawasaki Heavy Industries Ltd., Dover Corporation, Lonza Group AG, Terumo Corporation, Sartorius AG, Charles River Laboratories International Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, Hamilton Company, Repligen Corporation, Cellares Inc., Ori Biotech Ltd., Autolus Therapeutics Plc.
North America was the largest region in the automated and closed cell therapy processing systems market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the automated and closed cell therapy processing systems market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the automated and closed cell therapy processing systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The automated and closed cell therapy processing systems market includes revenues earned by entities by providing services such as cell separation and isolation, quality control integration, genetic modification, and cell activation. The market value includes the value of related goods sold by the service provider or included within the service offering. The automated and closed cell therapy processing systems market also includes sales of control systems, single-use consumables, automated cell washing systems, and closed-system fluid handling components. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Automated And Closed Cell Therapy Processing Systems Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses automated and closed cell therapy processing systems market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for automated and closed cell therapy processing systems ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The automated and closed cell therapy processing systems market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.